Regulatory concerns at various phases of drug development.

Presents a review of US Food and Drug Administration regulatory concerns at each phase of drug development. New drugs based on modifications of available agents; Drugs acting through novel mechanisms to alter plasma lipoprotein levels and structure; Therapies whose presumed salutary actions in decreasing atherosclerotic disease risk are via nonlipid effects.